An interventional study of High intensity interval training (HIIT) and Moderate intensity continuous training (MICT) in Prediabetic State, sponsored by Medical University of Vienna. Status unknown at 1 site in Austria. Open to male participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-09.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Basic science
This trial investigates if high intensity interval training is more effective than moderate intensity continuous training in suppressing platelet reactivity and hepatic fat content in prediabetic individuals.
Background:
The prevalence of type 2 diabetes mellitus (T2DM) is rising dramatically. T2DM represents a major cause for cardiovascular disease -related mortality and morbidity and increasingly burdens healthcare systems. While the fundamental pathomechanism of T2DM is insulin resistance of muscle and adipose tissue, recent studies demonstrate that insulin resistance in T2DM also occurs in platelets. As insulin directly inhibits platelet function, this mechanism might contribute to platelet activation and platelet hyperreactivity, which were in fact detected in diabetic patients. Since (inadvertent) platelet activation is causally linked to the development of atherosclerosis and atherothrombosis, regulation of platelet function is of utmost importance. Exercise training, performed on a regular basis has been shown to reduce morbidity and mortality in sedentary and diseased populations. Furthermore, exercise training improves whole body insulin sensitivity - however, it is currently unclear, if exercise training also affects insulin sensitivity of platelets. Recently, a time-saving interval training protocol has been adapted for T2DM-patients. Since this adapted high intensity interval training (HIIT) needs a fractional time commitment of exercise training according to current guidelines, HIIT possibly represents a promising instrument to increase adherence to exercise and thereby reduce T2DM morbidity.
Aims:
The primary aim of this study is to investigate the effect of 12 weeks of HIIT vs. continuous training (CT) on platelet insulin sensitivity and platelet (hyper)reactivity in prediabetic patients.
Secondary aims are to assess the effect of HIIT and CT on whole body insulin sensitivity and fitness in prediabetic patients as well as on various parameters of platelet function and on the hepatic fat content.
Hypotheses:
Our main hypothesis is that HIIT increases platelet insulin sensitivity and thereby decreases platelet activation/reactivity in patients with prediabetes. Methods: 44 prediabetic (see inclusion criteria) patients will be enrolled in this study. Patients will randomly be assigned to a HIIT group (committed to a supervised training program) or a CT group. After initial examinations (supervised graded exercise test, platelet function tests, oral glucose tolerance test, measurement of the hepatic fat content via FibroScan®), supervised training will be performed over a period of 12 weeks. Tests performed at the beginning of the study will be repeated after the training period.
999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.
This study's planned enrollment of 44 is below the median of 65 across 844 interventional studies indexed under Prediabetic State.
Browse Prediabetic State studies →Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks: * 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test * 30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test. * 10 minutes with 30% of maximal power output.
Behavioral: High intensity interval training (HIIT)
3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks: * 5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test * 30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output * 10 minutes with 30% of maximal power output.
Behavioral: Moderate intensity continuous training (MICT)
Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
EC50 (half-maximal effective concentration) of TRAP-6 (thrombin-receptor activating peptide) in terms of surface CD62P (=platelet selectin, P-selectin) expression: group differences after 12 weeks of training
Time frame: 12 weeks
EC50 of insulin in terms of intraplatelet VASP (vasodilator-stimulated phosphoprotein)-phosphorylation: group differences after 12 weeks of training
Time frame: 12 weeks
whole body insulin sensitivity
Time frame: 12 weeks
Maximal oxygen consumption
Unit: ml/min/kg bodymass
Time frame: 12 weeks
EC50 of other platelet agonists in terms of various platelet activation markers
Time frame: 12 weeks
EC50 of prostacyclin in terms of intraplatelet VASP-phosphorylation
Time frame: 12 weeks
Transient elastography (FibroScan®) controlled attenuation parameter (CAP)
The controlled attenuation parameter (CAP) has demonstrated good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD
Time frame: 12 weeks
Fatty Liver Index (FLI)
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna